Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in:

Open Access 01-12-2024 | Ovarian Cancer | Original research

Imaging tumor and ascites-associated macrophages in a mouse model of metastatic ovarian cancer

Authors: Catherine A. Foss, Flonné Wildes, Delia Mezzanzanica, Franca Podo, Chien-Fu Hung, Santosh Yadav, Marie-France Penet Vidaver

Published in: EJNMMI Research | Issue 1/2024

Login to get access

Abstract

Background

Tumor-Associated Macrophages (TAMs) play a critical role in the pathogenesis and progression of ovarian cancer, a lethal gynecologic malignancy. [124I]iodo-DPA-713 is a PET radiotracer that is selectively trapped within reactive macrophages. We have employed this radioligand here as well as a fluorescent analog to image TAMs associated with primary tumors, secondary pulmonary metastases and gastrointestinal tract-associated macrophages, associated with ascites accumulation in a syngeneic mouse model of metastatic ovarian cancer. Intact female C57BL/6 mice were engrafted with ID8-Defb29-VEGF tumor pieces. One month after engraftment, the mice were selected for positive bioluminescence to show primary and secondary tumor burden and were then scanned by PET/MRI with [124I]iodo-DPA-713, observing a 24 h uptake time. PET data were overlayed with T2-weighted MRI data to facilitate PET uptake tissue identity. Additionally, mice were imaged ex vivo using Near IR Fluorescence (NIRF), capturing the uptake and sequestration of DPA-713-IRDye800CW, a fluorescent analog of the radioligand used here. Additionally, cell culture uptake of DPA-713-IRDye680LT in ID8-DEFb29-VEGF, IOSE hTERT and RAW264.7 cells was conducted to measure tracer uptake in ovarian cancer cells, ovarian epithelial cells and macrophage.

Results

PET/MRI data show an intense ring of radiotracer uptake surrounding primary tumors. PET uptake is also associated with lung metastases, but not healthy lung. Mice displaying ascites also display PET uptake along the gastrointestinal tract while sham-operated mice show minimal gastrointestinal uptake. All mice show specific kidney uptake. Mice imaged by NIRF confirmed TAMs uptake mostly at the rim of primary tumors while 1 mm secondary tumors in the lungs displayed robust, homogeneous uptake of the radio- and fluorescent analog. Ex vivo biodistribution of [124I]iodo-DPA-713 showed that contralateral ovaries in middle-stage disease had the highest probe uptake with tissues sampled in mid- and late-stage disease showing increasing uptake.

Conclusion

[124I]iodo-DPA-713 and DPA-713-IRDye800CW sensitively identify and locate TAMs in a syngeneic mouse model of metastatic ovarian cancer.
Appendix
Available only for authorised users
Literature
1.
Mathieu KB, et al. Screening for ovarian cancer: imaging challenges and opportunities for improvement. Ultrasound Obstet Gynecol. 2018;51(3):293–303.PubMedPubMedCentralCrossRef
2.
Beiderwellen K, et al. 18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol Imaging. 2015;42(1):56–65.PubMedCrossRef
3.
Gupta V, Yull F, Khabele D. Bipolar Tumor-Associated macrophages in Ovarian Cancer as targets for Therapy. Cancers (Basel), 2018. 10(10).
4.
Takaishi K, et al. Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci. 2010;101(10):2128–36.PubMedPubMedCentralCrossRef
5.
Etzerodt A et al. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. J Exp Med, 2020. 217(4).
6.
Yin M, et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016;126(11):4157–73.PubMedPubMedCentralCrossRef
7.
Lecker LSM, et al. TGFBI Production by macrophages contributes to an immunosuppressive microenvironment in Ovarian Cancer. Cancer Res. 2021;81(22):5706–19.PubMedPubMedCentralCrossRef
8.
Jiang Q, et al. Ultrasound Molecular Imaging as a potential non-invasive diagnosis to detect the margin of Hepatocarcinoma via CSF-1R targeting. Front Bioeng Biotechnol. 2020;8:783.PubMedPubMedCentralCrossRef
9.
Sun X, et al. Ultrasound mediated Destruction of LMW-HA-Loaded and Folate-Conjugated Nanobubble for TAM Targeting and Reeducation. Int J Nanomed. 2020;15:1967–81.CrossRef
10.
Daldrup-Link HE, et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res. 2011;17(17):5695–704.PubMedPubMedCentralCrossRef
11.
Makela AV, Foster PJ. Imaging macrophage distribution and density in mammary tumors and lung metastases using fluorine-19 MRI cell tracking. Magn Reson Med. 2018;80(3):1138–47.PubMedCrossRef
12.
Zhang C, et al. Noninvasive imaging of CD206-Positive M2 macrophages as an early biomarker for Post-chemotherapy Tumor Relapse and Lymph Node Metastasis. Theranostics. 2017;7(17):4276–88.PubMedPubMedCentralCrossRef
13.
Terry SY et al. (1)(1)(1)In-anti-F4/80-A3-1 antibody: a novel tracer to image macrophages. Eur J Nucl Med Mol Imaging, 2015. 42(9): pp. 1430-8.
14.
Papadopoulos V, Fan J, Zirkin B. Translocator protein (18 kDa): an update on its function in steroidogenesis. J Neuroendocrinol, 2018. 30(2).
15.
Zinnhardt B, et al. TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. Neuro Oncol. 2020;22(7):1030–43.PubMedPubMedCentralCrossRef
16.
Albert NL, et al. TSPO PET for glioma imaging using the novel ligand (18)F-GE-180: first results in patients with glioblastoma. Eur J Nucl Med Mol Imaging. 2017;44(13):2230–8.PubMedCrossRef
17.
Unterrainer M, et al. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative (18)F-GE-180 PET study. Eur J Nucl Med Mol Imaging. 2020;47(6):1368–80.PubMedCrossRef
18.
Wehrl HF, et al. Preclinical and translational PET/MR Imaging. J Nucl Med. 2014;55(Supplement 2):S11–8.CrossRef
19.
Corovic A, et al. Somatostatin receptor PET/MR Imaging of Inflammation in patients with large Vessel vasculitis and atherosclerosis. J Am Coll Cardiol. 2023;81(4):336–54.PubMedPubMedCentralCrossRef
20.
Foray C, et al. Interrogating Glioma-Associated Microglia and Macrophage Dynamics under CSF-1R therapy with Multitracer in vivo PET/MRI. J Nucl Med. 2022;63(9):1386–93.PubMedPubMedCentralCrossRef
21.
Foss CA, et al. Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713. J Infect Dis. 2013;208(12):2067–74.PubMedPubMedCentralCrossRef
22.
Ruiz-Bedoya CA, et al. (124)I-Iodo-DPA-713 Positron Emission Tomography in a Hamster model of SARS-CoV-2 infection. Mol Imaging Biol. 2022;24(1):135–43.PubMedCrossRef
23.
Copeland BT, et al. Imaging and characterization of macrophage distribution in mouse models of human prostate Cancer. Mol Imaging Biol. 2019;21(6):1054–63.PubMedCrossRef
24.
Foss CA, et al. Biodistribution and Radiation Dosimetry of (124)I-DPA-713, a PET Radiotracer for Macrophage-Associated inflammation. J Nucl Med. 2018;59(11):1751–6.PubMedPubMedCentralCrossRef
25.
Foss CA, et al. Molecular imaging of inflammation in the ApoE -/- mouse model of atherosclerosis with IodoDPA. Biochem Biophys Res Commun. 2015;461(1):70–5.PubMedPubMedCentralCrossRef
26.
Foss CA, et al. Imaging Macrophage Accumulation in a murine model of chronic pancreatitis with (125)I-Iodo-DPA-713 SPECT/CT. J Nucl Med. 2017;58(10):1685–90.PubMedPubMedCentralCrossRef
27.
Roby KF, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21(4):585–91.PubMedCrossRef
28.
Zhang L, et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol. 2002;161(6):2295–309.PubMedPubMedCentralCrossRef
29.
Janat-Amsbury MM, et al. Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer. Anticancer Res. 2006;26(4B):2785–9.PubMed
30.
Conejo-Garcia JR, et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med. 2004;10(9):950–8.PubMedCrossRef
31.
32.
33.
Iorio E, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005;65(20):9369–76.PubMedCrossRef
34.
Zeibig S, et al. Effect of the oxLDL binding protein Fc-CD68 on plaque extension and vulnerability in atherosclerosis. Circ Res. 2011;108(6):695–703.PubMedCrossRef
35.
Savoie JC, Thomopoulos P, Savoie F. Studies on mono- and diiodohistidine. I. The identification of iodohistidines from thyroidal iodoproteins and their peripheral metabolism in the normal man and rat. J Clin Invest. 1973;52(1):106–15.PubMedPubMedCentralCrossRef
36.
Marginedas-Freixa I et al. Induction of ATP Release, PPIX Transport, and Cholesterol Uptake by Human Red Blood cells using a New Family of TSPO ligands. Int J Mol Sci, 2018. 19(10).
37.
38.
Ascencio M, et al. Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy. Lasers Surg Med. 2008;40(5):332–41.PubMedCrossRef
39.
Lu H et al. Fluorescence Spectroscopy Study of Protoporphyrin IX in Optical tissue simulating liquid phantoms. Mater (Basel), 2020. 13(9).
40.
41.
Ordonez AA, et al. Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob Agents Chemother. 2015;59(1):642–9.PubMedCrossRef
42.
43.
44.
45.
46.
Adhikary T, et al. Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. BMC Genomics. 2017;18(1):243.PubMedPubMedCentralCrossRef
47.
48.
49.
50.
Jung KY, et al. Cancers with higher density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates. J Pathol Transl Med. 2015;49(4):318–24.PubMedPubMedCentralCrossRef
51.
Vinogradov S, Warren G, Wei X. Macrophages associated with tumors as potential targets and therapeutic intermediates. Nanomed (Lond). 2014;9(5):695–707.CrossRef
52.
Nimmagadda S, Penet MF. Ovarian Cancer Target Theranostics Front Oncol. 2019;9:1537.PubMed
53.
Moughon DL, et al. Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian Cancer. Cancer Res. 2015;75(22):4742–52.PubMedPubMedCentralCrossRef
54.
Zeng Y, et al. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J. 2019;33(5):6596–608.PubMedPubMedCentralCrossRef
55.
56.
Rickard BP et al. Malignant ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and therapy response. Cancers (Basel), 2021. 13(17).
57.
Reinartz S, et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014;134(1):32–42.PubMedCrossRef
58.
Parayath NN, et al. Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer. Cancer Lett. 2019;461:1–9.PubMedPubMedCentralCrossRef
Metadata
Title
Imaging tumor and ascites-associated macrophages in a mouse model of metastatic ovarian cancer
Authors
Catherine A. Foss
Flonné Wildes
Delia Mezzanzanica
Franca Podo
Chien-Fu Hung
Santosh Yadav
Marie-France Penet Vidaver
Publication date
01-12-2024
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2024
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-024-01157-8

Other articles of this Issue 1/2024

An automated pheochromocytoma and paraganglioma lesion segmentation AI-model at whole-body 68Ga- DOTATATE PET/CT

Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours

Potential application of [18F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma

Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor

Increased lesion detectability in patients with locally advanced breast cancer—A pilot study using dynamic whole-body [18F]FDG PET/CT

The efficacy of short acquisition time using 18F-FDG total-body PET/CT for the identification of pediatric epileptic foci